Dr. Cindy Roegge completed her Ph.D. from the University of Illinois at Urbana-Champaign in Neuroscience. Her thesis work was on the neurodevelopmental effects of environmental contaminants such as polychlorinated biphenyls (PCBs) and methyl mercury in the laboratory of Dr. Susan Schantz. Dr. Roegge completed post-doctoral work with Dr. Ed Levin at Duke University Medical Center before taking an industry position as GLP study director at the contract research organization WIL Research in Ashland, Ohio (later purchased by Charles River). Dr. Roegge was also an Oak River Institute for Science and Education (ORISE) fellow in the Neurotoxicology Division at the FDA National Center for Toxicological Research in Jefferson, Arkansas, working with Dr. Merle Paule. Dr. Roegge then began her career in Medical Device Toxicology at Medtronic in 2011. She also worked as a toxicologist in drug development for central nervous system diseases at Upsher-Smith Laboratories and later as part of Proximagen, where the team received FDA approval for the combination product Nayzilam nasal spray containing midazolam as a rescue medication for the short-term treatment of seizure clusters. Dr. Roegge returned to Medtronic in 2018 to join the Targeted Drug Delivery Research team working on therapy expansion for the SynchroMed™ II fully implantable and programmable drug infusion pump along with the Ascenda™ intrathecal catheter for targeted drug delivery to the intrathecal space surrounding the spinal cord for current treatment of severe pain and spasticity. Dr. Roegge holds DABT board certification, has published 10 articles in peer-reviewed journals, co-authored a book chapter, presented numerous scientific posters, and has recently served as Councilor for the Northland Society of Toxicology Regional Chapter.